New anti-HIV drug interactions, toxicities, and dosing options.
Bartnof
H S
HS
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000928:Antidepressive Agents / Q000009:adverse effects; D056486:Chemical and Drug Induced Liver Injury; D002986:Clinical Trials as Topic; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D015507:Drugs, Investigational; D005260:Female; D013006:Growth Hormone / Q000627:therapeutic use; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008055:Lipids / Q000097:blood; D008060:Lipodystrophy / Q000139:chemically induced* / Q000517:prevention & control; D008297:Male; D008691:Methadone / Q000378:metabolism; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*
D019380:Anti-HIV Agents; D000928:Antidepressive Agents; D015507:Drugs, Investigational; D017320:HIV Protease Inhibitors; D008055:Lipids; D018894:Reverse Transcriptase Inhibitors; D013006:Growth Hormone; D008691:Methadone